Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer

Next Previous
Trial Profile

TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; BCG; Gemcitabine; Mitomycin
  • Indications Bladder cancer; Carcinoma
  • Focus Adverse reactions
  • Acronyms TRIO Bladder

Most Recent Events

  • 01 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 03 Mar 2020 Planned initiation date changed from 1 Jan 2020 to 1 Jun 2020.
  • 27 Nov 2019 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top